Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer. In this multicenter, randomized, noninferiority trial, we ...
Please provide your email address to receive an email when new articles are posted on . Skipping sentinel lymph node biopsy can be considered for node-negative, HR-positive, HER2-negative early breast ...
A test that combines clinicopathologic factors and a tumor’s gene expression profile (CP-GEP) reliably identified patients with a less than 10% risk for a positive sentinel lymph node biopsy — though ...
Development and validation of prediction models for 5-year and 10-year ipsilateral breast tumor recurrence after breast-conserving surgery. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Lymph node excision (LNEx) for patients with stage III melanoma with one clinically positive node: Excision of Lymph Node trial (EXCILYNT). Background: High-risk clinical stage II melanoma patients ...
Omitting SLNB in older patients with early-stage, HR-positive, HER2-negative breast cancer showed similar safety and efficacy to performing the procedure. The BOOG 13-08 trial demonstrated comparable ...
Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment. Targeted axillary dissection is used for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results